155 related articles for article (PubMed ID: 31189811)
1. [Efficacy and Safety of Paclitaxel plus Ramucirumab Therapy for Unresectable or Recurrent Gastric Cancer].
Tsujio G; Toyokawa T; Fukuoka T; Tamura T; Ohira G; Shibutani M; Yamazoe S; Nagahara H; Kimura K; Amano R; Tanaka H; Muguruma K; Yashiro M; Maeda K; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2019 May; 46(5):895-899. PubMed ID: 31189811
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
[TBL] [Abstract][Full Text] [Related]
3. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
Murakami K; Takeno A; Masuzawa T; Imada A; Takase K; Toya K; Yukawa Y; Kawai K; Sakamoto T; Katsura Y; Ohmura Y; Kagawa Y; Hata T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2020 Mar; 47(3):493-495. PubMed ID: 32381926
[TBL] [Abstract][Full Text] [Related]
6. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
Kimura M; Usami E; Teramachi H; Yoshimura T
J Oncol Pharm Pract; 2018 Sep; 24(6):403-411. PubMed ID: 28436252
[TBL] [Abstract][Full Text] [Related]
9. [The Clinical Effect of Ramucirumab in the Treatment of Advanced Gastric Cancer in Our Hospital].
Kenno S; Takahashi S; Noguchi K; Yamagami H; Ishizu H; Takahashi M
Gan To Kagaku Ryoho; 2018 Jan; 45(1):79-81. PubMed ID: 29362314
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Experience of Ramucirumab for Treating Advanced Gastric Cancer].
Kimura Y; Makari Y; Mikami J; Kamigaki S; Ikejima A; Fujii C; Sawada G; Nakahira S; Yamamura J; Nakata K; Yamamoto T; Ikeda N; Tsujie M; Fujita J; Ohzato H
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1193-1196. PubMed ID: 27760936
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
12. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
Zhang X; Zhou L; Zhou C; Shen L
Adv Ther; 2024 Jun; 41(6):2112-2132. PubMed ID: 38619719
[TBL] [Abstract][Full Text] [Related]
13. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ramucirumab/nab-paclitaxel for Previously Treated Advanced Gastric Cancer in Community Hospitals.
Hashida S; Tanaka N; Takahashi Y; Onoda Y; Colvin HS; Ohashi R; Okamoto K
Acta Med Okayama; 2021 Apr; 75(2):133-138. PubMed ID: 33953419
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Recurrent Gastric Cancer with Grade 3 Proteinuria Caused by Ramucirumab plus Paclitaxel Therapy].
Kimura Y; Makari Y; Mikami J; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Fujita J; Furukawa H; Yasuda T
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1080-1082. PubMed ID: 29394540
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy.
Kakuta T; Yabusaki H; Bamba T; Aizawa M; Nogami H; Nomura T; Matsuki A; Maruyama S; Takii Y; Nakagawa S
Int J Clin Oncol; 2021 Apr; 26(4):684-693. PubMed ID: 33389346
[TBL] [Abstract][Full Text] [Related]
17. [Effect of Hypoalbuminemia on Severe Neutropenia Induced by Paclitaxel Monotherapy and Paclitaxel plus Ramucirumab Combination Therapy in Patients with Gastric Cancer].
Nakazawa Y; Kageyama A; Harada D; Kitamura M; Mitsumori N; Kawakubo T
Gan To Kagaku Ryoho; 2019 May; 46(5):901-905. PubMed ID: 31189812
[TBL] [Abstract][Full Text] [Related]
18. [A Case of an Elderly Patient with Unresectable Gastric Cancer Treated by Paclitaxel and Ramucirumab].
Kimura Y; Makari Y; Mikami J; Yoshimura J; Inoue T; Sawada G; Nakahira S; Yamamura J; Kamigaki S; Nakata K; Yamamoto T; Ikeda N; Tsujie M; Fujita J; Ohzato H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2404-2406. PubMed ID: 28133336
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of Neutropenia and Usages of Antihypertensive Drugs in Patients Treated with Ramucirumab plus Paclitaxel Therapy].
Kawaguchi M; Kawakami K; Aoyama T; Tomomatsu T; Hama T; Takahari D; Chin K; Yamaguchi K; Yamaguchi M
Gan To Kagaku Ryoho; 2022 Aug; 49(8):873-878. PubMed ID: 36046973
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Successfully Treated with Paclitaxel plus Ramucirumab].
Miyamoto K; Tadano Y; Itoh R
Gan To Kagaku Ryoho; 2021 Jan; 48(1):113-114. PubMed ID: 33468738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]